- Personal FinanceCompare Online BrokersTop StocksAlternative Investing
- CryptoGet StartedNFTs
Innate Pharma (NASDAQ:IPHA), Quotes and News Summary
Innate Pharma (NASDAQ: IPHA)
Earnings
see more| H1 2022 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED)2022-09-04 | ||||||
| REV | |||||||
| FY 2021 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -0.650 | ||||||
| REV | 28.255M |
Analyst Ratings
see more| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|
Innate Pharma Questions & Answers
You can purchase shares of Innate Pharma (NASDAQ: IPHA) through any online brokerage.
Other companies in Innate Pharma’s space includes: Molecular Partners (NASDAQ:MOLN), Macrogenics (NASDAQ:MGNX), Outlook Therapeutics (NASDAQ:OTLK), Impel Pharmaceuticals (NASDAQ:IMPL) and Vaxxinity (NASDAQ:VAXX).
The latest price target for Innate Pharma (NASDAQ: IPHA) was reported by SVB Leerink on Wednesday, May 11, 2022. The analyst firm set a price target for 11.00 expecting IPHA to rise to within 12 months (a possible 279.31% upside). 4 analyst firms have reported ratings in the last year.
The stock price for Innate Pharma (NASDAQ: IPHA) is $2.9 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for Innate Pharma.
Innate Pharma’s H1 earnings are confirmed for Sunday, September 4, 2022.
There is no upcoming split for Innate Pharma.
Innate Pharma is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.